CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,951,125
- in 9 filings, $8.0M under 10b5-1 plans
Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Cohen Joshua B −$4.0M Co-Chief Executive Officer sold 4% of stake
- Klee Justin B. −$4.0M Co-Chief Executive Officer sold 4% of stake
- FRATES JAMES M −$1.6M Chief Financial Officer sold 18% of stake
- MILNE GEORGE M JR −$831K Director sold 4% of stake
- Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-15 | Quimi Daphne Director | Purchase | +2,250 | $1.89 | $4K | 5,000 |
| 2024-05-15 | Mazzariello Gina Chief Legal Officer | Sale 10b5-1 | −10,455 | $1.88 | $20K | 151,477 |
| 2024-05-14 | Quimi Daphne Director | Purchase | +2,750 | $1.89 | $5K | 2,750 |
| 2024-04-16 | FRATES JAMES M Chief Financial Officer | Grant or award | +91,180 | 225,964 | ||
| 2024-04-16 | FRATES JAMES M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2024-04-16 | Cohen Joshua B Co-Chief Executive Officer | Grant or award | +179,850 | 3,202,852 | ||
| 2024-04-16 | Cohen Joshua B Co-Chief Executive Officer | Grant or award · Stock Option (right to buy) | +380,000 | 380,000 | ||
| 2024-04-16 | Mazzariello Gina Chief Legal Officer | Grant or award | +80,560 | 161,932 | ||
| 2024-04-16 | Mazzariello Gina Chief Legal Officer | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2024-04-16 | Klee Justin B. Co-Chief Executive Officer | Grant or award | +179,850 | 3,139,158 | ||
| 2024-04-16 | Klee Justin B. Co-Chief Executive Officer | Grant or award · Stock Option (right to buy) | +380,000 | 380,000 | ||
| 2024-04-16 | Bedrosian Camille L Chief Medical Officer | Grant or award | +96,910 | 155,243 | ||
| 2024-04-16 | Bedrosian Camille L Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2024-03-14 | Zeiher Bernhardt G Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2024-03-05 | Cohen Joshua B Co-Chief Executive Officer | Sale | −4,135 | $18.73 | $77K | 3,023,002 |
| 2024-03-05 | Klee Justin B. Co-Chief Executive Officer | Sale | −4,135 | $18.73 | $77K | 2,959,308 |
| 2024-03-05 | Mazzariello Gina Chief Legal Officer | Sale | −1,540 | $18.73 | $29K | 81,372 |
| 2024-03-05 | FRATES JAMES M Chief Financial Officer | Sale | −1,792 | $18.73 | $34K | 134,784 |
| 2024-02-26 | FRATES JAMES M Chief Financial Officer | Grant or award | +40,000 | 152,035 | ||
| 2024-02-26 | FRATES JAMES M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 |
Page 8 of 19 · 362 trades